Optimization of Exocrine Pancreatic Insufficiency in Pancreatic Adenocarcinoma Patients
Nutrients · 2024
DOI: 10.3390/nu16203499 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Jaclyn V Moore und 4 weiteren Autor:innen. Beteiligte Einrichtung: Norton Cancer Institute, Louisville, KY 40202, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Exocrine Pancreatic Insufficiency, Adenocarcinoma, Enzyme Replacement Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alcresta Therapeutics.
Abstract (Originalsprache)
Background/Objectives: This study explores the optimization of exocrine pancreatic insufficiency (EPI) management in pancreatic adenocarcinoma patients, focusing on the scientific advancements and technological interventions available to improve patient outcomes, including oral pancreatic enzyme replacement therapy (PERT) and immobilized lipase cartridge (RELiZORB®). This was a prospective Institutional Review Board (IRB)-approved study from October 2019 through to August 2021 at the Louisville Medical Center in collaboration with Norton Healthcare and the University of Louisville Division of Surgical Oncology. Patients with a diagnosis of pancreatic adenocarcinoma (Stage 2 or 3) who underwent oncologic surgical resection were included in this study.
Methods
Patients were contacted at pre-defined intervals (prior to surgery, before hospital discharge, and 2, 4, 6, and 12 weeks after surgery) to complete nutrition evaluation, EPI assessment, and quality of life questionnaires to identify the severity and frequency of gastrointestinal (GI) symptoms.
Results
EPI symptoms were reported in 28 of the 35 total patients studied (80%). Jejunostomy tubes were placed during oncologic surgery in 25 of the 35 total patients studied (71%), and 12 of the 25 patients with a jejunostomy tube utilized enzyme cartridges to manage EPI symptoms while on supplemental tube feeding (48%). EPI symptoms were reported in 8 of the 10 patients without a feeding tube (80%), and their EPI symptoms were managed with PERT alone. EPI interventions, both oral PERT and immobilized cartridges, were associated with a decrease in EPI symptoms after surgery and improved quality of life (QOL).
Conclusions
Overall, early optimization of EPI is crucial to enhance overall patient care, return to oncology therapy after surgery, and improve quality of life in pancreatic adenocarcinoma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Norton Cancer Institute, Louisville, KY 40202, USA.
- Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, KY 40202, USA.
ORCID-Profile: Michael E Egger, Robert C G Martin
Förderung
- Alcresta Therapeutics
Zitieren
APA
Moore, J. V., Scoggins, C. R., Philips, P., Egger, M. E., & Martin, R. C. G. (2024). Optimization of Exocrine Pancreatic Insufficiency in Pancreatic Adenocarcinoma Patients. Nutrients. https://doi.org/10.3390/nu16203499
Vancouver
Moore JV, Scoggins CR, Philips P, Egger ME, Martin RCG. Optimization of Exocrine Pancreatic Insufficiency in Pancreatic Adenocarcinoma Patients. Nutrients. 2024. doi:10.3390/nu16203499
BibTeX
@article{Moore2024,
author = {Moore, Jaclyn V and Scoggins, Charles R and Philips, Prejesh and Egger, Michael E and Martin, Robert C G},
title = {Optimization of Exocrine Pancreatic Insufficiency in Pancreatic Adenocarcinoma Patients},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16203499}
}
EUVIMED